Board of directors

Born: 1952.

Other current assignments: Rolfsen is board member of Cinclus Pharma Holding AB and Rolfsen Consulting AB (as of which she also is CEO). Rolfsen is partner in Serendipity Partners.

Experience: Rolfsen has 16 years’ experience in leading positions within pre-clinical research and development at Pharmacia AB. She has been responsible for the early clinical organization at Quintiles Europe and CEO of Quintiles Scandinavia for a total of 11 years. Moreover, she has been a board member of several listed companies since 2005. She holds a PhD in Pharmacology from Uppsala University where she also was associate professor during 9 years.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: Yes.

Shareholding in InDex: Direct holding of 268 400 shares and indirect holding of 487 344 shares.

Born: 1950.

Other current assignments: Hacksell is chairman of the board of Medivir AB, Annexin Pharmaceuticals AB and SynAct Pharma AB, and board member of Active Biotech AB.

Experience: Hacksell has over 25 years of international R&D management experience from both large pharmaceutical and biotech companies as well as over 10 years of experience as public company CEO. Hacksell has been CEO and chairman of the board of Cerecor.Hacksell was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from being a private start-up to becoming a public multibillion dollar company. He has previously held various senior executive positions at Astra AB and has held the position of professor in organic chemistry at Uppsala University. He has a PhD from Uppsala University.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: Yes.

Shareholding in InDex: Direct holding of 408 000 shares.

Born: 1956.

Other current assignments: Hansson is chairman of the board of Ignitus AB, Cinclus Pharma Holding AB and Sixera Pharma AB as well as board member of Medivir AB and QureTech Bio AB.

Experience: Former head of Life Science Investments at Industrifonden. Previously Hansson has more than 25 years’ experience from pharma and biotech industry in executive position at KabiGen, Symbicom AB, AstraZeneca AB, Karolinska Development AB and BioVitrum AB and as CEO for Arexis AB. He has a PhD from Umeå University.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: Yes.

Shareholding in InDex: Indirect holding of 432 000 shares.

Born: 1974.

Other current assignments: Karl Tobieson is CEO of Linc AB. Karl is also chairman of the board of MedCap AB, T&S Förvaltning AB and Tobieson & Svennewall AB, board member of Alder Therapeutics, Melius Pharma, BRF Hornblåsaren, board deputy of Gram Medicin AB and OGGroup AB.

Experience: Karl Tobieson was CEO of MedCap AB (publ) 2008-2020. Prior to that, he ran a corporate finance company together with a partner and before that he was Investment Manager at Centrecourt and Cell Innovation. Karl Tobieson began his career as a trainee at Volvo. Karl Tobieson has a master’s degree in mechanical engineering with a focus on industrial economics, from the Royal Institute of Technology in Stockholm.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: No.

Shareholding in InDex: